Navigation
Nutritional, functional, and psychological considerations for incretin-based therapies in adults—an EASO, EFAD, and ECPO Consensus Statement
The use of incretin-based therapies, such as GLP-1 receptor agonists and dual GLP-1–GIP receptor agonists, has significantly reshaped the landscape of obesity treatment. These therapies not only promote considerable weight loss but also offer cardiometabolic advantages that can lead to improvements in complications related to obesity, physical functioning, quality of life, and psychological health for numerous patients.
Nevertheless, there are potential nutritional, functional, and psychological risks associated with these treatments. Side effects such as diminished appetite, rapid weight loss, digestive issues, and changes in eating behavior may pose challenges for some individuals. Therefore, the EASO–EFAD–ECPO Consensus Statement emphasizes the practical aspect of nutrition and psychology during the administration of incretin-based therapies.
This consensus synthesizes existing research regarding medical nutrition therapy. Key recommendations include setting protein intake goals during weight loss, ensuring dietary quality, and managing gastrointestinal side effects. Maintaining muscle mass and physical performance is critical; thus, ensuring adequate protein intake and engaging in progressive resistance training are advised.
Moreover, the statement highlights the psychological hurdles encountered during incretin treatment, such as changes in food reward systems and effects on coping mechanisms and social connections. Psychological evaluations and integrated support systems are suggested to address these challenges effectively.
Monitoring progress during weight loss is crucial, focusing on dietary quality, potential micronutrient deficiencies, and functional performance, and, when necessary, body composition assessments. To ensure equitable access and adherence to these therapies, strategies must be developed to mitigate disparities.
Practitioners are encouraged to involve patients in shared decision-making about the initiation, adjustment, or cessation of incretin-based therapies, balancing the physical and psychological risks of continuing versus halting treatment. Finally, the statement outlines future research priorities, including the need for extended studies on micronutrient levels, macronutrient requirements, changes in eating patterns, musculoskeletal health, unique dosing regimens, and post-treatment maintenance strategies to enhance safety, effectiveness, and overall patient experience. [NPID: GLP-1, Incretin-based therapies, food reward, psychological effect]
Year: 2026
